News
17. October 2025
Exciting days at ChemBioParis2025 – hands-on discussions with prospective users
It’s been a pleasure introducing our new F1 at the ORYL Photonics and sharing instrument demonstrations with many great scientists and collaborators — especially colleagues from EU-OPENSCREEN.
Hands-on discussions with users always bring valuable insights, and it’s inspiring to see how much interest there is in advancing screening technologies together.
A big thank you to everyone who stopped by and to Nathan Dupertuis and Robert Harmel for brining our efforts to potential to potential users!
14. October 2025
F1 prototype is departing Bordeaux and heading to USC (Spain)!
Last week our consortium visited the Optics and Laser Technology Center ALPhANOV in Bordeaux to see the first FASS instrument.
The result is astonishing. The instrument fits easily on a table and the software is intuitive. This is a great milestone for the project thanks to an amazing cooperation between ALPhANOV and ORYL Photonics.
The F1 will now be shipped to our EU-OPENSCREEN partner site at Universidade de Santiago de Compostela to validate and test its performance in a real user environment. Later this year, a second instrument will be shipped to Hochschule für Life Sciences FHNW for the development of pharmaceutical applications.
We are impatiently waiting for the new results!
22. May 2025
Our partner ORYL Photonics wins the prestigious Ignite award for the best start-up!
Today the FASS team leaves the SLAS (Society for Laboratory Automation and Screening) Europe 2025 with amazing news:
Our partner ORYL Photonics wins the prestigious Ignite award for the best start-up!
Congratulations to Orly Tarun and Nathan Dupertuis and thanks to all partner inside and outside the FASS consortium who contributed to this success!
15. May 2025
Meet us at the SLAS Europe 2025 (20-22 May) in Hamburg!
The FASS Consortium is excited to take part in this year’s SLAS Europe conference
Poster Presentation
Catch Robert Harmel from EU-OPENSCREEN at our Poster to hear more about our work. Let’s connect and chat about FASS technology—whether you’re interested in a demo, want to collaborate, or have samples you’d like us to measure!
Innovation Spotlight
Our consortium partner Oryl Photonics has been selected for Innovation AveNEW, and is one of the finalists of the Ignite Award! Don’t miss the chance to meet Nathan Dupertuis and Orly Tarun from ORYL at the exhibition on May 21–22 and explore how solubility and aggregation measurements are being redefined!
Looking forward to seeing many of you in Hamburg!
9. May 2025
Our partner Oryl Photonics was selected for the innovation AveNEW at SLAS Europe!
Nathan Dupertuis (founder) comments::
I am looking forward to exhibit in the Innovation AveNEW corner at SLASEurope2025 in Hamburg, Germany organised by SLAS (Society for Laboratory Automation and Screening)! We will be just next our friends from PHABIOC.
Come find us in the exhibition on May 21st and 22nd to learn more about Oryl Photonics’ technology redefining solubility and aggregation measurement!
There will be a big announcement at the conference. Stay tuned!
The FASS – Fast and Accurate Solubility for Sustainability team will also be presenting a poster at the conference, check it out!
2. May 2025
Pioneering Business Development for FASS
Oryl Photonics and WP3
Bringing cutting-edge research to the pharmaceutical industry requires more than innovation—it demands a clear path to commercialization. In WP3, we focus on business development, ensuring that the FASS instrument not only meets scientific needs but is also market-ready.
Our efforts include:
- Developing and validating a business plan for commercialization and go-to-market strategies.
- Protecting intellectual property rights to safeguard innovations.
- Meeting regulatory standards and establishing a robust supply chain for production.
Leading this effort is Oryl Photonics, an innovative technology company and EPFL spin-off dedicated to redefining solubility and aggregation measurements in the pharmaceutical industry. Using advanced nonlinear light scattering, Oryl is driving the development of the FASS instrument with contributions to:
- Prototype development in WP1
- Business development in WP3: Introducing the FASS instrumen to the market and establishing its value proposition for pharmaceutical and biotechnological companies.
By combining Oryl’s expertise with the WP3 team’s focus on strategy, we’re transforming the FASS instrument into a viable product that saves resources and advances drug research and development.
17. April 2025
Meet us in Berlin at the Helmholtz Drug Discovery Conference!
We’re excited to promote FASS at the Helmholtz Drug Discovery Conference between 28-30 April 2025 in Berlin!
FASS offers a disruptive solubility measurement for Drug Discovery – fast, accurate, and highly sensitive measurements designed for the needs of pharmaceutical and chemical industries.
Curious about how we’re redefining solubility measurements? Come find Robert Harmel and Yasemin Furtun Uçal from EU-OPENSCREEN at our poster and let`s chat!
We’re looking forward to connecting and discussing with fellow scientists, innovators, and collaborators at Hashtag#HDDC2025.
20. March 2025
Connecting Innovation with Customers in WP2
Actions of EU-OPENSCREEN
How do we transform innovative ideas into market-ready instruments? In WP1, our focus is on developing a THow do we ensure groundbreaking technology meets the needs of its future users? In WP2, the focus is on customer development—validating the value proposition of the FASS instrument and preparing it for market success. Here’s how it works:
- Real-world demonstrations of FASS to potential customers, tested against industry standards.
- Collaborations with scientists from industry and academia to test samples and experience the technology first-hand.
EU-OPENSCREEN, coordinator of FASS, brings unparalleled expertise in early drug discovery and a network of 36 partner sites across 9 countries. Our role includes:
- Leading project management and communication to ensure seamless collaboration.
- Testing the FASS instrument at the BioFarma Research Group at Universidade de Santiago de Compostela (USC), our partner site to validate its potential.
- Leveraging our extensive network of potential customers and early adopters to bring this technology to the forefront of the scientific community.
By aligning innovation with customer needs, WP2 is turning cutting-edge technology into practical solutions for academia and industry.
👀 Want to learn more? Contact us to explore FASS’s capabilities!
4. March 2025
Advancing Prototype Development in WP1
ALPhANOV in Action
How do we transform innovative ideas into market-ready instruments? In WP1, our focus is on developing a TRL 6 demonstrator system that combines cutting-edge performance with reliability and ease of use.
Here’s where ALPhANOV, a leader in laser and optical technologies, plays a critical role. With their expertise in 3D design, electronics, and optical simulations, they’re driving the engineering of a compact, compliant laboratory instrument ready for pre-industrialization.
This new system will feature:
- An improved optical and electronic design for enhanced performance and reliability.
- A user-friendly, integrated software package tailored to market needs.
- A design compliant with regulations, ensuring safety and usability for end users.
Together, the WP1 team and ALPhANOV are paving the way to prototype instruments that will redefine industry standards and prepare for mass production.
25. September 2024
We are hiring!
Postdoc in Novel Drug Solubility Analytics (80-90%)
Our consortium member Prof. Martin Kuentz from Fachhochschule Nordwestschweiz FHNW has opened a new postdoctoral position to work on our project.
If you want to contribute to the future of pharmaceutical R&D with cutting-edge technology, you can contact him directly!
You can find the job advertisement here:
https://apply.refline.ch/655298/4010/pub/1/index.html
